Recruitment

Recruitment Status
Completed
Estimated Enrollment
70

Summary

Conditions
Diabetes Mellitus
Type
Interventional
Phase
Phase 4
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Min Age
18
Max Age
110
Gender
Both

Description

The current professional organization guidelines recommend insulin as the preferred treatment for hospitalized patients. It is recommended that most critically ill patients should receive insulin infusion therapy and non-critically ill patients should receive basal bolus insulin therapy in the hospi...

The current professional organization guidelines recommend insulin as the preferred treatment for hospitalized patients. It is recommended that most critically ill patients should receive insulin infusion therapy and non-critically ill patients should receive basal bolus insulin therapy in the hospital. The study will test the hypothesis that treatment with saxagliptin is non-inferior to treatment with basal bolus insulin in this group of patients during their hospital stay. The study will evaluate the effect of saxagliptin, a DPP4 inhibitor, on glycemic control in non-critically ill hospitalized patients with type 2 diabetes mellitus (T2DM) The primary outcome will be mean daily blood glucose levels during hospital days 2 to 5. The study is designed to detect a non-inferiority margin of 20% in the saxagliptin group as compared to the control group

Locations

Boston, Massachusetts, 02115
Boston, Massachusetts, 02115

Tracking Information

NCT #
NCT02182895
Collaborators
Not Provided
Investigators
  • Principal Investigator: Rajesh K Garg, MD Brigham and Women's Hospital
  • Rajesh K Garg, MD Brigham and Women's Hospital